I became Professor Emeritus in 2000. Until then I was the Program Director of the Cardiovascular Pathophysiology Training Program (CVPTG) and a now the proposed Associate Director o Dr. Stephen Meredith. As Director of this program, I have been committed to the training of future cardiovascular scientists. In addition to training of graduate students and post-doctoral fellows in my own laboratory, I participate in graduate and medical education in a number of ways. I have been a member of the Graduate Student Affairs Committee in the MPMM (Molecular Pathology and Molecular Medicine) program for several decades. Until very recently I led a weekly journal club attended by all students in the MMPM graduate program and all trainees supported by the CVPTG. I also continue to teach in both graduate and medical school courses. My own research is focused on atherogenesis, and the roles of apolipoproteins and, more recently, the immune system in this pathological process. This work is all done in collaboration with Dr. Catherine Reardon. We are studying the mechanisms by which apoA-I mimetic peptides function to attenuate atherosclerosis in murine models. We have had a great deal of experience in studying murine atherosclerosis over the last couple of decades. We have studied the role of the immune system and atherosclerosis in the apoE-/- and LDLR-/- models. We have studied global immunodeficiency, NKT cell deficiency and overproduction, and cellular adoptive transfer of NKT cells and B-1 cells to immunodeficient animals. We are now studying the role of the TNF superfamily co stimulatory molecules, LIGHT, lymphotoxin and their two receptors, LTβR and HVEM, in regulating lipoprotein metabolism and atherosclerosis. Recent work has focused on the properties of 4F-based peptides and their tandem cousins in influencing lipoprotein metabolism and atherosclerosis. In addition to our studies on the biophysical properties of these peptides, we observed that 4F administered intraperitoneally reduces early atherosclerosis, but in selective anatomic sites. That is, it reduces atherogenesis in three vascular sites (aortic root, ascending aorta and innominate artery), but no such effect was noted in the established lesions i.e. when 8 weeks of treatment is begun in 20 week old apoE-/- mice. Much of our recent work is predicated on having established murine models, e.g., the development of an HDL- less model i.e. apoE-/- apoA-I-/- mice. Using these models, we have for some years been studying the structure of apoA-I and the way it contributes to HDL subclass formation. Additionally our laboratory has been engaged in experiments that explore the strain ( C57Bl6 and FVB) based difference in HDL level, composition and function, particularly the ability of the different apo A-1s to protect against atherogenesis. In all of our atherosclerosis we have drawn attention to the atherosusceptibility of different macrovascular sites. More recently we have studied the differential function of adipose tissue derived apo E In addition to my educational and scientific work, I am heavily involved in editorial activities. I am an associate editor of the Journal of Lipid Research, and on the editorial boards of three other journals devoted to experimental pathobiology.

Dr. Bhatt serves as Chief Medical Officer at American Hospital Association. Dr. Jay Bhatt served as Chief Health Officer at the Illinois Hospital Association. He most recently served as Managing Deputy Commissioner/Chief Strategy and Innovation Officer for the Chicago Department of Public Health (CDPH). In this role he oversees policy, planning, public relations, quality improvement as well as innovation. His visions is to bring together health systems, community based organizations, the private sector and CDPH to advance population health using big data, predictive analytics and tech innovation. Dr. Jay Bhatt is a National Health Service Corps Scholar and a Geriatrician from University of Michigan. He completed an internal medicine residency at Cambridge Health Alliance, a teaching affiliate of Harvard Medical School where he was a clinical fellow. In 2012. He graduated from the University of Chicago in 1999 with a degree in Economics. In 2008, Dr. Bhatt received both his medical degree from the PCOM, and his Master in Public Health degree from the University of Illinois at Chicago School of Public Health. In 2012 he received his Masters in Public Administration from the Harvard Kennedy School of Government as a Zuckerman and Commonwealth Fund Minority Health Policy Fellow at Harvard Medical School.

Marshall H. Chin, MD, MPH, FACP, Richard Parrillo Family Professor of Healthcare Ethics in the Department of Medicine at the University of Chicago, is a general internist with extensive experience improving the care of vulnerable patients with chronic disease. He is Director of the Robert Wood Johnson Foundation (RWJF) Finding Answers: Disparities Research for Change National Program Office; Director of the RWJF Reducing Health Care Disparities Through Payment and Delivery System Reform Program Office; Director of the Chicago Center for Diabetes Translation Research; Associate Chief and Director of Research in the Section of General Internal Medicine; Co-Director of the John A. Hartford Foundation Center of Excellence in Geriatrics; and Associate Director of the MacLean Center for Clinical Medical Ethics at the University of Chicago. He is a member of the National Quality Forum Measure Applications Partnership Coordinating Committee. Dr. Chin is leading the evaluation of a Commonwealth Fund project that is implementing the patient-centered medical home in 65 safety net clinics across five states. He is also improving diabetes care and outcomes on the South Side of Chicago through health care system and community interventions supported by grants from NIDDK and the Merck Foundation. He serves on the CDC Community Preventive Services Task Force and the editorial board of Health Services Research. Dr. Chin is the President of the Society of General Internal Medicine. He has won mentoring awards from the Society of General Internal Medicine and University of Chicago. Dr. Chin is a graduate of the University of California at San Francisco School of Medicine and completed residency and fellowship training in general internal medicine at Brigham and Women’s Hospital, Harvard Medical School.

Dr. Elbert Huang is Associate Professor of Medicine, Director of the Center for Translational and Policy Research of Chronic Diseases, and Associate Director of the Chicago Center for Diabetes Translation Research at the University of Chicago. From 2010-2011, he served as a Senior Advisor in the Office of the Assistant Secretary for Planning and Evaluation, Department of Health and Human Services. Dr. Huang is a general internist who studies clinical and health care policy issues at the intersection of diabetes, aging, and health economics. He has performed seminal translational diabetes research studies applying methods from cost-effectiveness analysis. In 2008, Dr. Huang led a widely cited study that explored the role of epidemiological modeling in the federal budget forecasting process on behalf of the Novo Nordisk’s National Changing Diabetes Program. He also performed the economic analyses of the Health Resources and Services Administration’s Health Disparities Collaboratives initiative of diabetes quality improvement in community health centers that serve the indigent. With this one study, he performed one of the first business case analyses from the perspective of the community health center as well as one of the first societal cost-effectiveness analyses of a quality improvement initiative. Dr. Huang’s research has been supported by the National Institutes of Health, the Centers for Disease Control and Prevention, the American Diabetes Association, and the Juvenile Diabetes Research Foundation. He has received numerous honors including the Research Paper of the Year Award from the Society of General Internal Medicine and elected membership to the American Society for Clinical Investigation. Dr. Huang received his A.B., M.D., and M.P.H. from Harvard University and came to the University of Chicago in 2001.

David C. Grossman, M.D., M.P.H., is senior investigator at the Group Health Research Institute, medical director for population and purchaser health strategy, and a practicing pediatrician at the Group Health healthcare system in Seattle, WA. He is also Professor of Health Services and Adjunct Professor of Pediatrics at the University of Washington. In his current role, he leads a group of Group Health leaders and researchers who address the design, promotion, delivery, and evaluation of population care services, including studies of the impact of Health Benefit Design changes.   Dr. Grossman holds numerous leadership positions within the professional community. He is the co-vice chair of the U.S. Preventive Services Task Force (member of since January 2008) and is also a current member of the Community Preventive Services Task Force. He recently concluded several terms as a member of the Board of Scientific Counselors of the Centers for Disease Control and Prevention's National Center for Injury Prevention and Control. Dr. Grossman is also a former member and officer of the board of directors of the Washington Health Alliance, a multi-stakeholder non-profit with a mission to improve the quality and value of healthcare in the State of Washington.

Dr. Press is currently an Assistant Professor of Medicine in the Section of Hospital Medicine at the University of Chicago. Her work primarily focuses on improving patient-centered education for underserved patients with chronic disease and limited health literacy through novel interventions in the community and hospital settings targeted at both patients and clinicians. Dr. Press earned degrees in public health and medicine from the University of Michigan, and completed her residency in the combined Internal Medicine-Pediatrics program at the University of Chicago. During her Hospitalist Scholars fellowship, Dr. Press led the development and implementation of the Chicago Breathe Project that provided inhaler education for 5 Chicago residency programs and 2 community sites serving minority patients with funding from the American College of Physicians Foundation. As part of the Robert Wood Johnson Finding Answers Disparities Research for Change project, she led a systematic review of interventions that aim to improve health disparities and care for minority populations with asthma. She completed work funded by an institutional KM1 on the comparative effectiveness of educational strategies (intensive “Teach to Goal” vs. brief in-person or video education) designed to improve hospitalized patients' ability to self-manage their asthma and COPD through promoting correct use of respiratory inhalers. She has since received an NIH K23 to continue this work and expand it to examine the utility of video module education for inhaler use. In addition to this work, Dr. Press is also conducting health literacy work, in which she has found that a non-trivial number of patients have poor vision, a risk that is increased in older patients, which also increases risk of worse self-management of chronic disease.

I went to Loyola Marymount University for my undergraduate years. I attended Ross University School of Medicine, graduated in 2000. From there I completed my residency in Internal Medicine at New York Hospital in NYC. Board Certified in Internal Medicine. Started in primary care in Los Angeles, CA. I later found CareMore Health Plan based in Cerritos, CA and became an extensivist which is a combination of hospitalist work, skilled nursing facility and outpatient clinic. Recently I became a Regional Medical Director for CareMore.